NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the CLARITY Phase 3 trial of solriamfetol in the treatment of major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms. CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is ...

PLYMOUTH, Mich. and ROLLE, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (Nasdaq: GTX) ("Garrett" or the "Company"), a leading differentiated automotive technology provider today announced its participation in the upcoming investor conference: Bank of America Global Automotive Summit (March 18, 2026) – Craig Balis, Chief Technology Officer and our Investor Relations team will host a company presentation and participate in investor meetings. About Garrett Motion Inc.A differentiated tech ...

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD) CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch ...

Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyFDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission seeking accelerated approvalTopline open label study data to support BLA submission expected in Q2 2026 Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-ha ...

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer ...

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, Fe ...

WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call ...

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson’s disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-02 ...

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit pro ...

AMD and Meta Announce Expanded Strategic Partnership to Deploy 6 Gigawatts of AMD GPUs The 6-gigawatt agreement expands on the companies’ existing strategic partnership and aligns roadmaps across silicon, systems and software to deliver AI platforms purpose-built for Meta’s workloads. News Highlights Meta is partnering with AMD to rapidly scale AI infrastructure and accelerate the development and deployment of cutting-edge AI modelsAMD and Meta agree to a definitive multi-year, multi-generation partner ...